Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) SVAa leading supplier of biopharmaceutical products in China, announced that from 01.01St to 3approx November in Frankfurt, Germany.
At booth no. 41G20, on the first floor of Hall 4, Messe Frankfurt, SINOVAC welcomes all CPHI visitors and presents its comprehensive portfolio. The company will introduce the only inactivated COVID-19 vaccine approved for children as young as 6 months of age, CoronaVac®; the quadrivalent influenza vaccine, QIV; the world’s leading enterovirus type 71 vaccine, Inlive®; the chickenpox vaccine, which provides 100% protection against moderate and severe cases; and two vaccines prequalified by WHO: Hepatitis A vaccine, Healive® and Sabin strain inactivated polio vaccine.
Helen Yang, Chief Business Officer of SINOVAC, said: “SINOVAC is an old friend of CPHI and we are excited to finally return to CPHI’s in-person event for the first time since the global outbreak of the COVID-19 pandemic. As always, we really appreciate the business potential of the platform and we plan to showcase many of our best products, especially those that are WHO approved and distributed to many countries around the world. We strive to introduce our latest cutting-edge technologies to our global partners develop more business opportunities.”
To meet SINOVAC on site, please feel free to visit booth #41G20 or contact Alice Chen via info@sinovac.com to make appointments.
About SINOVAC
Sinovac Biotech Ltd., (SINOVAC) is a China-based biopharmaceutical company focused on the research and development, manufacturing and marketing of vaccines that protect against human infectious diseases.
SINOVAC’s product portfolio includes vaccines against COVID-19, Enterovirus 71 (EV71) infected hand, foot and mouth disease (HFMD), hepatitis A, seasonal influenza, pneumococcal disease, pandemic influenza H5N1 (bird flu), H1N1 influenza ( swine flu…
